Matthew Greenhawt on Muck Rack

Matthew Greenhawt

New York
As seen in: Color Research & Application, Wiley, Wiley Online Library, ScienceDirect, Archives of Disease in Childhood, U.S. News and World Report, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, The New England Journal of Medicine, The Lancet and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Matthew

Contact Matthew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

|
By Matthew Greenhawt, Sara Anvari, Nicolette J. T. Arends, Deborah Albright
| tu-dresden.de
Abstract Externe IDs PubMed 39956162 Schlagworte Anaphylaxis, Desensitization, Epicutaneous immunotherapy, Open-label study, Peanut allergy, Pediatrics, VIASKIN patch
Open in Who Shared Issue with article?

Pharmacokinetics and pharmacodynamics of AQST-109: phase 3 results comparing epinephrine sublingual film with intramuscular injection

|
By David B.K. Golden, Matthew Greenhawt, Nils Confer
| Annals of Allergy, Asthma & Immunology Verified
Intramuscular (IM) epinephrine administered via manual injection, autoinjector, or as a nasal spray, are the current first-line treatments for anaphylaxis. AQST-109 is a needle- and device-free sublingual alternative epinephrine formulation in late-stage clinical development. To compare the pharmacokinetics (PK) and pharmacodynamics (PD) of single dose (SD) and repeat doses (RD) AQST-109 and IM epinephrine in healthy adults.
Open in Who Shared Issue with article?

One Year Later: How Intranasal Epinephrine Is Changing Emergency Allergy Treatment

|
By Matthew Greenhawt, Brian Schroer, Ryan Haumschild, Thomas Casale Verified, Chelsie Derman Verified, Victoria Johnson Verified
| consultantlive.com
On August 9, 2024, the FDA approved the first needle-free epinephrine nasal spray under the name neffy (ARS Pharmaceuticals) for the emergency treatment of anaphylaxis in adults and children—a significant milestone in allergy care.1 One year later, this intranasal option has expanded the treatment landscape for severe allergic reactions, offering a discreet and easy-to-use alternative to autoinjectors.
Open in Who Shared View Duplicates (4) Issue with article?
See all 110 licensed articles (124 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified